Chapter 1 Executive Summary

Chapter 2 Introduction - The Erectile Dysfunction Market Will See Large Growth Rates Throughout the Period, 2007-2012

• 2.1 The Viagra Revolution
• 2.2 Erectile Dysfunction Defined
• 2.3 ED Prevalence is Increasing
• 2.4 Male Hormonal Changes Due to Age
• 2.5 How an Erection Occurs
• 2.6 Penile Anatomy and Erection
• 2.7 Primary and Secondary ED
• 2.8 The Causes of Secondary ED
• 2.9 ED Due to Systemic Diseases and Ageing 2.10 Neurogenic Erectile Dysfunction
• 2.11 Vascular Causes of Erectile Dysfunction
• 2.12 Drug-Induced Erectile Dysfunction
• 2.13 Summary of All ED Treatments
• 2.14 Drug Therapy
  • 2.14.1 Mechanism of Action of PDE-5 Inhibitors
  • 2.14.2 Viagra (Pfizer)
  • 2.14.3 Cialis (Eli Lilly/Icos)
  • 2.14.4 Levitra (GSK/Bayer AG)

Chapter 3 The World Market for ED Drugs

• 3.1 The ED Market Will See Large Growth Rates
• 3.2 Viagra Will Lose Dominance of the ED Market
• 3.3 Cialis Will Achieve Blockbuster Status
• 3.4 Viagra Will Lose Market Dominance to Cialis
• 3.5 Levitra Shows Strong Growth
• 3.6 Shortest Time to Erection is a Major Market Advantage
• 3.7 Brand Awareness Will Play a Key Part in Maintaining Viagra's Position in the Market
• 3.8 Brand Switching Will Increase Individual Drug Sales But Not Expand the Market
• 3.9 Market Expansion Depends on Persuading ED Men to Seek Treatment
• 3.10 Pfizer Currently Leads the ED Market
• 3.11 The US Dominates the World Market for ED Drugs

Chapter 4 Forces Affecting the ED Market

• 4.1 SWOT Analysis of the ED Market
• 4.2 An Expanding Patient Population Constitutes the Principal Driver in the ED Market
• 4.3 The Principal Restraints in the ED Market
• 4.4 Major Success in the ED Drugs Market and Opportunities to Target
• 4.5 Adverse Events Over ED Drugs
  • 4.5.1 FDA Revise Label Changes to ED Drugs After Reported Sudden Hearing & Vision Loss
  • 4.5.2 FDA Immediately Recall `Natural` ED Drugs After Major Concerns Over Safety
  • 4.5.3 Studies Link ED to Heart Disease and Smoking
• 4.6 Lack of Adequate Reimbursement Limits Potential of ED Drugs
• 4.7 ED Surgery - A Last Resort When Drug-Based Treatments Fail
  • 4.7.1 Penile Venous Surgery
  • 4.7.2 Penile Arterial Revascularization
  • 4.7.3 Penile Implants
  • 4.7.4 Internal Penile Pump
• 4.8 ED Awareness is Key for Market Expansion
• 4.9 Uprima (Apomorphine) is a Market Failure

Chapter 5 Female Sexual Dysfunction (FSD) and Future Market Possibilities

• 5.1 Female Sexual Arousal
• 5.2 Over 45% of All Women Will Experience Some Degree of FSD
• 5.3 Genital Vascular Congestion Essential for Normal Sexual Function in Both Men and Women
• 5.4 The Medical Causes of Female Sexual Dysfunction
• 5.5 Medical Drugs Can Cause FSD
• 5.6 There are Times in a Women's Life of Natural Decreased Sexual Desire
• 5.7 The Treatments for Female Sexual Dysfunction
• 5.8 The Role of Estrogen and Progesterone in Female Sexual Desire is not Understood
• 5.9 The Role of Testosterone in Female Sexual Desire is Not Clear
• 5.10 The Treatment of Female Sexual Arousal Disorders
• 5.11 Anorgasmia Responds Well to Therapy
• 5.12 The Successful Treatment for Dyspareunia Approaches 90%
• 5.13 The Pharmacological Treatment of FSD and Future Market Possibilities

Chapter 6 Pipeline Developments in the Erectile Dysfunction Market

• 6.1 Abbott's ABT- 670 in Phase I Trials for ED
• 6.2 Agents in Phase II of Clinical Development
  • 6.2.1 Pfizer's UK 369003
  • 6.2.2 Inotek's INO 1001
  • 6.2.3 Schering-Plough's Dasantafil
  • 6.2.4 Vivus' Avanafil
  • 6.2.5 Abbott's ABT-724
• 6.3 SK Chemicals' Mirodenafil in Pre-Registration for ED
• 6.4 New Drugs for ED Must Have a Short Onset Time
• 6.5 Discussion of Current Pipeline Developments
• 6.6 Summary of Pipeline Drugs for ED, Phase I and Above

Chapter 7 The Counterfeit ED Drugs Market

• 7.1 Drug Counterfeiting: An Overview
• 7.2 The Different Types of Counterfeit Drugs
• 7.3 Viagra Counterfeits
• 7.4 Country Specific Patent Laws and How it can Influence Drug
• Counterfeiting
• 7.5 The Growth of Internet Pharmacies Has Aided Viagra Sales
• 7.6 The Privacy Factor as a Driver of Online Sales
• 7.7 Online Viagra
• 7.8 Internet Erectile Dysfunctional Drugs Sales
• 7.9 Combating the Counterfeiters

Chapter 8 Conclusion

• 8.1 ED is a Serious Condition with High Prevalence
• 8.2 ED Market Analysis
• 8.3 Market Drivers
• 8.4 Market Restraints
• 8.5 New Products May Not Expand the Market Further
• 8.6 The Time to Erection is the Most Important Aspect of Any Novel ED Drug
• 8.7 The Key to Market Expansion is to Get More ED Men to Seek Medical Advise
• 8.8 Strategies for Marketing: Changing Men's Minds
• 8.9 Outlook for the Future of the ED Market

List of Tables

• Table 1.1 Top ED Drugs Revenue ($m), 2006
• Table 2.1 Major Drug Therapies for ED, 2006
• Table 2.2 Viagra, Cialis, and Levitra Revenues ($m) and Market Share
• (%), 2006
• Table 3.1 The Total World ED Drugs Market Forecast ($m), 2007-2012
• Table 3.2 Worldwide Revenues ($m) for ED Drugs, 2007-2012
• Table 3.3 The Worldwide Market Share by Revenue (%) for ED Drugs,
• 2007-2012
• Table 3.4 Viagra, Levitra and Cialis: Specific Product Advantages, 2007
• Table 3.5 Top 10 Leading Companies in the ED Market, Revenue ($m) and
• Market Share (%), 2006
• Table 3.6 Market Share by Country Region by Revenue (%), 2006
• Table 4.1 A SWOT Chart for the ED Market
• Table 5.1 Types of Female Sexual Dysfunction and Prevalence
• Table 5.2 Drugs that Cause Decreased Sexual Desire
• Table 5.3 Drugs that Cause Decreased Sexual Arousal
• Table 6.1 Agents in Phase II of Clinical Development for ED, 2007
• Table 6.2 Summary of Pipeline Drugs for ED, Phase I and Above, 2007

List of Figures

• Figure 2.1 Worldwide Revenues ($m) for the ED Market, 2007-2012
• Figure 3.1 Total ED Drugs World Market Revenue Forecast ($m), 2007-2012
• Figure 3.2 Worldwide Revenues ($m) for ED Drugs, 2007-2012
• Figure 3.3 The Worldwide Market Share (%) By Revenue for Viagra, Levitra
• and Cialis, 2007-2012
• Figure 3.4 Market Share (%) by Revenue of ED Drugs, 2006
• Figure 3.5 Market Share (%) by Revenue of ED Drugs, 2009
• Figure 3.6 Market Share (%) by Revenue of ED Drugs, 2012
• Figure 3.7 Leading Companies in the ED Market, Market Share (%), 2006
• Figure 3.8 Market Share by Country Region (%), 2006
• Figure 8.1 Total Sales of ED Drugs ($m), 2007-2012
• Figure 8.2 Sales of the Leading ED Drugs ($m), 2007-2012

List of Companies Mentioned

• Abbott
• Alza
• Bayer
• Dong-A
• Eczacibasi
• FDA
• Genentech
• GSK
• In2Gen
• Inotek
• Johnson & Johnson's
• Kohl Medical
• Lilly
• MHRA
• Palatin
• Pfizer
• Schering-Plough
• SK Chemicals
• Spimaco
• Surface Logix
• Synvista
• Tanabe
• UCB
• Vectura
• Vivus
• WHO